By the year 2050, the number of Americans living with Alzheimer’s disease is expected to triple to 14 million people.

The dramatic rise in 2050 is expected to cost American society $1 trillion in today’s dollars. $1 trillion would include a nearly FIVE-FOLD increase in government spending in Medicare and Medicaid. In 2016, one in every five Medicare dollars was spent on Alzheimer’s and other dementias. By 2050, it will be one in every three and every 33 seconds, another American will be diagnosed with Alzheimer’s.

Yet, no drugs available today slow or stop Alzheimer’s damage to neurons. Few new drugs are in clinical trials. The failure rate of clinical trials of new drugs has been more than 99%.

That’s one of the lowest success rates in any therapy.

So, researchers have shifted their focus from treating Alzheimer’s to preventing it. And, according to a study, aspirin could possibly be the answer.

According to the Alzheimer’s Association, Alzheimer’s disease is defined as “Alzheimer’s is a type of dementia that affects memory, thinking and behavior. Symptoms eventually grow severe enough to interfere with daily tasks. Alzheimer’s is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer’s disease accounts for 60-80% of dementia cases.”

Capitol Imaging Services is proud to be a Louisiana statewide sponsor of their 2021 Walk to End Alzheimer’s events occurring this fall. Events are scheduled to be held over a two-month period from September to November.

Capitol Imaging Services is the largest independent radiology practice of its type serving the southeastern United States. Not only do we perform the scan such as an MRI or PET/CT, we also provide the radiology expertise to review test images and issue important findings to physicians and other healthcare providers.

Click here to read the Newsweek story.

Image used under license from freestock.com